Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T21:19:03.839Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale—supportive analyses from a Phase 3 study

Published online by Cambridge University Press:  19 June 2017

Leslie Citrome ,
Robert Risinger ,
Andrew J. Cutler ,
Yangchun Du ,
Jacqueline Zummo ,
Henry A. Nasrallah  and
Bernard L. Silverman
Leslie Citrome*
Affiliation:
New York Medical College, Valhalla, New York, USA
Robert Risinger
Affiliation:
NeuroRx Pharmaceuticals, Wilmington, Delaware, USA
Andrew J. Cutler
Affiliation:
Meridien Research, Bradenton, Florida, USA
Yangchun Du
Affiliation:
Alkermes, Inc., Waltham, Massachusetts, USA
Jacqueline Zummo
Affiliation:
Alkermes, Inc., Waltham, Massachusetts, USA
Henry A. Nasrallah
Affiliation:
Saint Louis University School of Medicine, St. Louis, Missouri, USA
Bernard L. Silverman
Affiliation:
Alkermes, Inc., Waltham, Massachusetts, USA
*
*Address for correspondence: Leslie Citrome, MD, MPH, 11 Medical Park Drive, Suite 106, Pomona, NY 10970, USA. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic that was evaluated for the treatment of schizophrenia in a randomized, placebo-controlled, Phase 3 study. Here, we present exploratory analyses of supportive efficacy endpoints.

Methods

Patients experiencing an acute exacerbation of schizophrenia received AL 441 mg intramuscularly (IM), AL 882 mg IM, or matching placebo IM monthly. Supportive endpoints included changes from baseline at subsequent time points in Clinical Global Impression-Severity (CGI-S) scale score; Positive and Negative Syndrome Scale (PANSS) Total score; PANSS Positive, Negative, and General Psychopathology subscale scores; PANSS Marder factors (post hoc); and PANSS responder rate. Overall response rate, based on PANSS Total score and Clinical Global Impression–Improvement (CGI-I) scale score, was also analyzed.

Results

Of 622 patients who were randomized, 596 had ≥1 post-baseline PANSS score. Patients were markedly ill at baseline (mean PANSS Total scores 92–94). Compared with placebo, CGI-S scores; PANSS Positive, Negative, and General Psychopathology subscale scores; and PANSS Marder factors were all significantly (p<0.001) improved by Day 85 with both AL doses, with significantly lower scores starting from Day 8 in most instances. Treatment response rates were significantly (p<0.001) greater with both doses of AL vs placebo.

Conclusion

AL demonstrated robust efficacy on CGI-S score, PANSS subscale scores, PANSS Marder factors, and response rates. Study limitations included use of a fixed dose for initial oral aripiprazole and fixed monthly AL doses without the option to individualize the oral initiation dosing or injection frequency for efficacy, tolerability, or safety.

Keywords

Antipsychotic treatmentaripiprazole lauroxilpsychotic symptomsresponseschizophrenia
Type
Original Research
Information
CNS Spectrums , Volume 23 , Issue 4 , August 2018 , pp. 284 - 290
Copyright
© Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.Google Scholar
2. Carbon, M, Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19(Suppl 1): 35–53.Google Scholar
3. Bobes, J, Arango, C, Garcia-Garcia, M, Rejas, J, CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry. 2010; 71(3): 280–286.Google Scholar
4. Keefe, RS, Harvey, PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012; 213: 11–37.Google Scholar
5. Mohamed, S, Rosenheck, R, Swartz, M, Stroup, S, Lieberman, JA, Keefe, RSE. Relationship of cognition and psychopathology to function impairment in schizophrenia. Am J Psychiatry. 2008; 165(8): 978–987.Google Scholar
6. Lehoux, C, Gobeil, M-H, Lefèbvre, A-A, et al. The five-factor structure of the PANSS: A critical review of its consistency across studies. Clin Schizophr Related Psychoses. 2009; 3(2): 103–110.Google Scholar
7. Marder, SR, Davis, JM, Chouinard, G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997; 58(12): 538–546.Google Scholar
8. Guy, W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, US Government Printing Office, US Department of Health, Education, and Welfare Publication No. 76–338; 1976: 218–222.Google Scholar
9. Meltzer, HY, Risinger, R, Nasrallah, HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015; 76(8): 1085–1090.Google Scholar
10. Aristada (aripiprazole lauroxil) extended-release injectable suspension, for intramuscular use [package insert]. Waltham, MA, USA: Alkermes Inc; Revised February 2017. http://aristada.com/hcp/ARISTADA-prescribing-information.pdf (accessed May 30, 2017).Google Scholar
11. Kane, JM, Carson, WH, Saha, AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002; 63(9): 763–771.Google Scholar
12. Kane, JM, Peters-Strickland, T, Baker, RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014; 75(11): 1254–1260.Google Scholar
13. Potkin, SG, Saha, AR, Kujawa, MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003; 60(7): 681–690.Google Scholar
14. ABILIFY (Aripiprazole) Tablets, ABILIFY DISCMELT (Aripiprazole) Orally Disintegrating Tablets, ABILIFY (Aripiprazole) Oral Solution, ABILIFY (Aripiprazole) Injection for Intramuscular use Only. [Package insert]. Revised February 2017. https://www.otsuka-us.com/media/images/AbilifyPI_538.pdf (accessed May 30, 2017).Google Scholar
15. Citrome, L. The ABC’s of dopamine receptor partial agonists —aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015; 69(11): 1211–1220.Google Scholar
16. Citrome, L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016; 9(2): 169–186.Google Scholar
17. Fusar-Poli, P, Kempton, MJ, Rosenheck, RA. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials. Int Clin Psychopharmacol. 2013; 28(2): 57–66.Google Scholar